StockMirror — Stock Screener

ROSSARI Q4 FY26 Results & Earnings Analysis

Sentiment: Neutral (Confidence: medium)

Earnings Summary

Rossari Biotech reported a strong finish to FY26 with record Q4 revenue and EBITDA, driven by volume growth across all segments. However, the outlook for FY27 is cautiously optimistic, with management guiding for at least 15% revenue growth but flat margins (12-13%) due to geopolitical risks (Middle East conflict), raw material cost inflation, and ongoing losses in B2C businesses. A key strategic shift is the rephasing of a large capex plan and a focus on divesting non-core, loss-making businesses to improve margins and reduce debt. The long-term story remains positive, anchored by new capacities, a new R&D facility, and a focus on high-margin segments (pharma, oil & gas). , , , ,

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management is focused on driving at least 15% revenue growth in FY27 while simultaneously taking steps to improve margins. This includes divesting low-margin B2C businesses, focusing on high-margin segments (pharma, oil & gas), and improving product mix. They are balancing growth with margin discipl

About Rossari Biotech Limited

Rossari Biotech Limited (ROSSARI) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More